Document Detail


PET-CT in recurrent ovarian cancer: impact on treatment planning.
MedLine Citation:
PMID:  18751410     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Positron emission tomography-computed tomography (PET-CT) is currently not established in the management of recurrent ovarian cancer. Here, its value in diagnosis and therapy planning was evaluated. PATIENTS AND METHODS: Seventy patients received PET-CT for suspicion of recurrent ovarian cancer. PET-CT and surgery were reviewed to analyze the accuracy in the diagnosis of recurrence and prediction of full resectability. RESULTS: PET-CT showed disease relapse in 63 of 70 patients, with full sensitivity and specificity. Thirty cases were operated on. PET-CT indicated full resectability in 24, but in fact only incomplete resection was possible in three cases. Thus sensitivity and specificity for the identification of full resectability were 100% and 66%, respectively. Seven negative results in PET-CT were confirmed by a relapse-free follow-up of 1 year. CONCLUSION: PET-CT offers reliable detection of recurrent ovarian cancer. Although diagnostic accuracy in the prediction of full resectability is limited, surgical planning is improved by identifying sites of intraperitoneal involvement.
Authors:
Miriam S Lenhard; Alexander Burges; Thorsten R C Johnson; Petra Stieber; Carolin Kümper; Nina Ditsch; Rainer Linke; Klaus Friese
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Anticancer research     Volume:  28     ISSN:  0250-7005     ISO Abbreviation:  Anticancer Res.     Publication Date:    2008 Jul-Aug
Date Detail:
Created Date:  2008-08-28     Completed Date:  2008-09-09     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8102988     Medline TA:  Anticancer Res     Country:  Greece    
Other Details:
Languages:  eng     Pagination:  2303-8     Citation Subset:  IM    
Affiliation:
Department of Obstetrics and Gynecology, Ludwig Maximilians University Munich, Campus Grosshadem, Munich, Germany. Miriam.Lenhard@med.uni-muenchen.de
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Aged, 80 and over
Combined Modality Therapy
Female
Fluorodeoxyglucose F18 / diagnostic use
Humans
Middle Aged
Neoplasm Recurrence, Local / drug therapy,  radionuclide imaging*,  surgery,  therapy*
Ovarian Neoplasms / drug therapy,  radionuclide imaging*,  surgery,  therapy*
Positron-Emission Tomography / methods
Radiopharmaceuticals / diagnostic use
Sensitivity and Specificity
Chemical
Reg. No./Substance:
0/Radiopharmaceuticals; 63503-12-8/Fluorodeoxyglucose F18

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Value of serum S-100B for prediction of distant relapse and survival in stage III B/C melanoma.
Next Document:  Huge primary retroperitoneal mucinous cystadenoma of borderline malignancy mimicking an ovarian mass...